Merck's Oral PCSK9 Inhibitor Could Pose A Future Threat After Early Trial Success
MK-0616 – administered orally – reduced LDL cholesterol in patients in two early clinical trials presented at the American Heart Association Scientific Sessions.
You may also be interested in...
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
Two years into leading Novartis' largest business unit, Novartis Pharmaceuticals president Marie-France Tschudin talked to Scrip about the US launch of inclisiran, US drug price reform and other challenges and opportunities for the industry.
The US FDA issued a complete response letter for inclisiran, delaying the launch of the RNAi-based PCSK9 inhibitor for high cholesterol.